Cita APA

Hashimoto, J., Garnero, P., van der Heijde, D., Miyasaka, N., Yamamoto, K., Kawai, S., . . . Nishimoto, N. (2010). Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: Data from the SAMURAI study. Springer Japan.

Citación estilo Chicago

Hashimoto, Jun, Patrick Garnero, Désirée van der Heijde, Nobuyuki Miyasaka, Kazuhiko Yamamoto, Shinichi Kawai, Tsutomu Takeuchi, Hideki Yoshikawa, y Norihiro Nishimoto. Humanized Anti-interleukin-6-receptor Antibody (tocilizumab) Monotherapy Is More Effective in Slowing Radiographic Progression in Patients With Rheumatoid Arthritis At High Baseline Risk for Structural Damage Evaluated With Levels of Biomarkers, Radiography, and BMI: Data From the SAMURAI Study. Springer Japan, 2010.

Cita MLA

Hashimoto, Jun, et al. Humanized Anti-interleukin-6-receptor Antibody (tocilizumab) Monotherapy Is More Effective in Slowing Radiographic Progression in Patients With Rheumatoid Arthritis At High Baseline Risk for Structural Damage Evaluated With Levels of Biomarkers, Radiography, and BMI: Data From the SAMURAI Study. Springer Japan, 2010.